X4 Pharmaceuticals (XFOR) Non Operating Income (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Non Operating Income for 10 consecutive years, with $236000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Income fell 55.3% year-over-year to $236000.0; the trailing twelve-month figure through Jun 2026 stood at -$2.3 million (down 153.1% YoY), and the FY2025 full-year result was $7.7 million, up 1145.33% from the prior year.
• Non Operating Income climbed to $236000.0 in Q2 2026 per XFOR's latest filing, from $65000.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $24.9 million in Q3 2023 and bottomed at -$29.9 million in Q2 2023.
• Historically, Non Operating Income has averaged $413888.9 across 5 years, with a median of -$432000.0 in 2022.
• The widest YoY moves for Non Operating Income: up 1825.61% in 2023, down 4585.27% in 2023.
• Over 5 years, Non Operating Income stood at -$3.5 million in 2022, then jumped by 273.7% to $6.1 million in 2023, then tumbled by 163.06% to -$3.8 million in 2024, then surged by 94.13% to -$226000.0 in 2025, then jumped by 204.42% to $236000.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $236000.0, $65000.0, and -$226000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.